22. Moyamoya disease Clinical trials / Disease details
Clinical trials : 14 / Drugs : 21 - (DrugBank : 14) / Drug target genes : 28 - Drug target pathways : 44
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031200402 | 23/04/2021 | 08/03/2021 | Search for abnormalities of fundus blood vessels in moyamoya disease | Search for abnormalities of fundus blood vessels in moyamoya disease | Moyamoya disease Moyamoya disease | For fluorescein fundus angiography, 500 mg of fluorescein (5 ml vial of aqueous solution containing 500 mg of fluorescein) and 25 mg of Ophthagreen (2 ml of blue indocyanine green) are dissolved in 2 ml of distilled water for injection and injected through the forearm of the elbow vein. In daily practice, diabetic retinopathy can be treated by using a diabetic retinal imaging system (optos). In daily practice, it is used for the diagnosis of diabetic retinopathy, uveitis, occlusive retinal vascular disease, and age-related macular degeneration. | Akiyama Hideo | NULL | Recruiting | >= 20age old | Not applicable | Both | 50 | N/A | Japan |